Stay updated on Nivolumab and Relatlimab in MMRd Cancers Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page revision label was updated from v3.5.2 to v3.5.3.
    Difference
    0.1%
    Check dated 2026-04-24T06:18:30.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:40:31.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    47 days ago
    Change Detected
    Summary
    Study status updated to Active, not recruiting and enrollment set to 38, with revised study dates. Contact information for the study team has been updated.
    Difference
    1%
    Check dated 2026-03-19T05:29:06.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    - Revision updated: v3.4.3 added; v3.4.2 removed.
    Difference
    0.1%
    Check dated 2026-03-12T02:27:35.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the government-funding notice and prior Revision: v3.4.1 from the page.
    Difference
    0.4%
    Check dated 2026-02-11T11:55:29.000Z thumbnail image
  8. Check
    90 days ago
    Change Detected
    Summary
    The page now displays a government funding notice about potential delays and the site revision tag updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:27:41.000Z thumbnail image

Stay in the know with updates to Nivolumab and Relatlimab in MMRd Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.